Equity · Healthcare
LTRN
NASDAQLantern Pharma Inc.
$2.89
−1.37% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
$4.0
$2.5
8 Jul
17 Jul
The line runs $3.11 on 8 July through $2.89 on 17 July, on a scale from $2.5 to $4.0. Days the market did not trade hold the previous close, flat.
Market cap
$36.9M
52-week range
$1.03 – $5.50
Avg volume
34.3K
as of Jul 17, 2026
Filings 4 sets
LTRN reported financials
SEC EDGARLTRN reported net income of −$17.1M for the fiscal year ended 31 Dec 2025.
Figure
Reported
Period
Net income
−$17.1M
31 Dec 2025
fiscal year
Diluted EPS
−$1.57
31 Dec 2025
fiscal year
Total assets
$8.6M
30 Jun 2026
at period end
Total equity
−$3.2M
30 Jun 2026
at period end
LTRN earnings
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
−$0.57
—
31 Mar 2026
Q1 2026
−$0.30
—
31 Dec 2025
FY 2025
−$1.57
—
30 Sep 2025
Q3 2025
−$0.39
—
30 Jun 2025
Q2 2025
−$0.40
—
31 Mar 2025
Q1 2025
−$0.42
—
31 Dec 2024
FY 2024
−$1.93
—
30 Sep 2024
Q3 2024
−$0.42
—
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
LTRN institutional holders
SEC EDGAR3 of the 45 institutional funds we track reported a LTRN position for the quarter ended 30 Jun 2026 — a combined $1.5M; the latest of those filings landed 02 Sep 2026.
Fund
Action
Shares
Value
LTRN fails-to-deliver
SECOn 24 Aug 2026, 16,546 shares of LTRN failed to deliver (about $39K).
Settlement date
Shares failed
Notional
% of shares out
24 Aug 2026
16,546
$39K
0.129%
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARValuation computed from SEC EDGAR filings